Antibe Therapeutics Inc. (TSX), a clinical-stage biotechnology company based in Toronto, Ontario, developing pain and inflammation-reducing drugs, was placed in receivership on April 22, 2024. The company had previously sought protection under the Companies' Creditors Arrangement Act (CCAA) on April 9 after being ordered to pay US$20 million plus costs and interest to its largest creditor, Nuance Pharma. Nuance had paid Antibe for the rights to market its lead drug in the Greater China Area but alleged that Antibe had excluded certain correspondence with Health Canada from the data room.

The court denied Antibe's request for an extension of the CCAA stay and granted the receivership application, citing that the company's entire business was centered on a drug far from commercialization. FTI was appointed as the receiver. Legal counsel involved in the case included Bennett Jones for Nuance Pharma, TGF for the receiver, Paliare Roland for Antibe, Norton Rose Fulbright for Deloitte as the former monitor, and Davies for Knight Therapeutics.